A phase II evaluation of all-trans-retinoic acid plus interferon alfa- 2a in stage IV melanoma: A Southwest Oncology Group Study

Vernon K. Sondak, P. Y. Liu, Lawrence E. Flaherty, William S. Fletcher, Phillip Periman, David R Gandara, Sarah A. Taylor, Stanley P. Balcerzak, Frank L. Meyskens

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

BACKGROUND: Interferon alfa has modest but definite activity in the treatment of metastatic melanoma and is the only agent currently available for adjuvant therapy of high-risk resected disease. A variety of retinoic acid derivatives have been shown to be synergistic with interferon alfa in vitro and in vivo, with nonoverlapping toxicities. If promising combinations of interferon alfa and retinoids could be developed for melanoma patients, they would have clinical relevance for the treatment of advanced as well as localized disease. PURPOSE: To determine the efficacy and toxicity of a combination of interferon alfa-2a and all-trans-retinoic acid in patients with measurable metastatic melanoma, the Southwest Oncology Group conducted a phase II clinical trial. PATIENTS AND METHODS: Fifty-seven patients with measurable metastatic melanoma (American Joint Committee on Cancer stage IV) were entered; five patients were unevaluable. Treatment consisted of oral all-trans-retinoic acid (37.5 to 75 mg/m2 orally twice daily for 21 days followed by 7 days' rest) plus subcutaneously administered interferon alfa- 2a (6 MU/m2 three times a week). RESULTS: Two complete and three partial responses were observed among 52 evaluable patients, for an objective response rate of 10% (95% confidence interval 3% to 21%). Responses were seen only in patients with pulmonary, nodal, or subcutaneous metastases, and lasted from 4 to 23+ months. Median survival for the 52 patients was 8 months. Side effects were tolerable but significant, with one case of grade IV anemia and 92% of patients experiencing at least grade II toxicity. Flu- like symptoms were the most commonly reported side effects. There was one case of grade III hyperlipidemia. CONCLUSION: The combination of recombinant human interferon alfa-2a with all-trans-retinoic acid did not result in a greater percentage of objective responses or a longer overall survival than that associated with interferon alfa alone. This combination cannot be recommended for further evaluation in melanoma in either the advanced disease or the adjuvant settings.

Original languageEnglish (US)
Pages (from-to)41-47
Number of pages7
JournalCancer Journal from Scientific American
Volume5
Issue number1
StatePublished - Jan 1999

Keywords

  • All-trans-retinoic acid
  • Interferon alfa
  • Melanoma
  • Phase II trial
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'A phase II evaluation of all-trans-retinoic acid plus interferon alfa- 2a in stage IV melanoma: A Southwest Oncology Group Study'. Together they form a unique fingerprint.

  • Cite this

    Sondak, V. K., Liu, P. Y., Flaherty, L. E., Fletcher, W. S., Periman, P., Gandara, D. R., Taylor, S. A., Balcerzak, S. P., & Meyskens, F. L. (1999). A phase II evaluation of all-trans-retinoic acid plus interferon alfa- 2a in stage IV melanoma: A Southwest Oncology Group Study. Cancer Journal from Scientific American, 5(1), 41-47.